Biophysics of the Immune System is
the research team led by Dr. Rubén Vicente. The main interest is
understanding the role of ion fluxes and membrane composition
regulation in the physiology of immune cells, having a special
interest in calcium signaling, zinc fluxes, and de novo ceramide
synthesis. The current research projects are:
Calcium signaling and
ORMDL3 pathophysiology
ORMDL3 is a transmembrane protein
located in the endoplasmic reticulum. This protein has been shown to
negatively regulate sphingolipid synthesis and to alter calcium
homeostasis. As a consequence, alterations in ORMDL3 expression levels
are associated with inflammatory diseases like asthma, inflammatory
bowel diseases, or rheumatoid arthritis. Our team is focused on
studying the mechanistic insights of ORMDL3 cellular function.
Zinc signaling in immune cells
Zinc is a trace element essential
for human health. Zinc deficiency is common in old adults,
vegetarians, and patients with chronic inflammatory diseases. This
condition causes immune dysfunction leading to an increased risk of
inflammatory and infectious diseases. However, the specific role of
zinc in the physiology of T-cells is still poorly characterized.
Zinc is known to affect T lymphocyte maturation, differentiation,
and cytokine production. Our laboratory has demonstrated that zinc
positively potentiates T-cell function by enhancing the three main
signaling activation pathways, AP-1, NF-kB, and NFAT1. In addition,
we have described that the Zip6 zinc transporter is essential for
proper T-cell activation. We aim to have a better knowledge of the
signaling events that modulate zinc in T to understand the benefits
and risks of zinc-based nutritional immunity.
NanoTarg: a
nanotechnological platform to treat cancer
Our team, together with the
NanoMedicine lab led by Dr. Pilar Rivera, is involved in the
development of NanoTarg, a novel nanotechnological platform to improve
the diagnosis and treatment of cancer. We have determined an
oncotarget to specifically accumulate nanocapsules in the tumoral
tissue and we are participating in the preclinical validation of the technology.